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Foregoing researches made on the N/OFQ system brought up a possible role for this system in cardiovascular 
regulation. In this study we examined how N/OFQ levels of the blood plasma changed in acute cardiovascular 
diseases. Three cardiac patient groups were created: enzyme positive acute coronary syndrome (EPACS, n = 10), 
enzyme negative ACS (ENACS, n = 7) and ischemic heart disease (IHD, n = 11). We compared the patients to 
healthy control subjects (n = 31). We found signifi cantly lower N/OFQ levels in the EPACS [6.86 (6.21–7.38) pg/
ml], ENACS [6.97 (6.87–7.01) pg/ml and IHD groups [7.58 (7.23–8.20) pg/ml] compared to the control group [8.86 
(7.27–9.83) pg/ml]. A signifi cant correlation was detected between N/OFQ and white blood cell count (WBC), 
platelet count (PLT), creatine kinase (CK), glutamate oxaloacetate transaminase (GOT) and cholesterol levels in the 
EPACS group. 
   Decreased plasma N/OFQ is closely associated with the presence of acute cardiovascular disease, and the severity 
of symptoms has a signifi cant negative correlation with the N/OFQ levels. We believe that the rate of N/OFQ 
depression is in association with the level of ischemic stress and the following infl ammatory response. Further 
investigations are needed to clarify the relevance and elucidate the exact effects of the ischemic stress on the N/OFQ 
system.
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More than a decade now that a new chapter has been opened in the research of the opioid 
system with Mollereau cloning a new member of the opioid receptor family, which was 
named opioid receptor like orphan receptor (ORL-1) because it was reminiscent of the opioid 
receptors on both structural and functional ground (21). A year later the endogenous ligand 
of the ORL-1 was identifi ed and named nociceptin (for its hyperalgesic effect on mice when 
administered intracerebroventricularly) and orphanin-FQ, because of the Phe and Gln amino 
acids on the ends of the peptide chain (21, 22). The ORL-1 receptor was renamed NOP 
receptor and the nociceptin/orphanin FQ peptide as N/OFQ in the current nomenclature by 
NC-IUPHAR. 
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NOP receptor shares a high degree of nucleotide sequence homology with each of the 
cloned μ-, δ- and κ-opioid receptors but, most notably, it resembles the κ-1 subtype (21). 
However it is naloxone insensitive, unlike all other opioid receptors (7). It is coupled to a Gi/o 
protein and it inhibits adenylyl cyclase and Ca2+-infl ux, and activates K+-effl ux in a manner 
similar to opioids (19). Neuroanatomical studies on rodents have shown that N/OFQ is 
distributed throughout the central nervous system, especially in regions known to participate 
in the regulation of autonomic and cardiovascular function (5). A study completed later on 
humans has shown that there is considerable similarity with the previous fi ndings in the rat 
central nervous system. The highest concentrations of N/OFQ were noticed in the dorsal 
central gray matter (periaqueductal gray), the locus coeruleus, the ventromedial nucleus of 
hypothalamus, the septum and the dorsal horn of the spinal cord. Evidence indicates that N/
OFQ has a signifi cant role in regulating the neurotransmission of the central nervous system 
(24). There is also evidence that N/OFQ has direct effects on different cardiovascular 
regulatory areas on rodents both in vitro and in vivo (6). Other study results have shown that 
N/OFQ has peripheral effects in cardiovascular regulation (12). 
In spite of the growing evidence that N/OFQ has a signifi cant role in cardiovascular 
regulation, studies having been made so far have concentrated mainly on its function in pain 
sensation and its possible use as a novel analgesic (9). Given that our limited knowledge on 
the N/OFQ system is based on studies made on rodents, human physiology remains relatively 
unclear (8). Furthermore, the results of the few human studies are controversial. It seems that 
the effect of N/OFQ is very much dependent on its dose and way of administration (16). 
Elevated plasma N/OFQ level was noticed in humans suffering from chronic pain (17), stroke 
(25), and different chronic liver diseases, such as Wilson’s disease (14), primary biliary 
cirrhosis and hepatocellular carcinoma (15). More recently, Fontana et al. (11) have found 
that the plasma N/OFQ level rises in patients with spontaneous episodes of angina. 
Given that the role of N/OFQ in human cardiovascular pathology becomes more and 
more focused, our main goal was to examine plasma N/OFQ levels in acute cardiovascular 
diseases. In this pilot study, we aimed to analyse the effect of severe ischemia on the plasma 
N/OFQ levels in the groups of enzyme positive acute coronary syndrome (ACS), enzyme 
negative ACS, and ischemic heart disease patients in a quiescent phase (IHD) and healthy 
controls. 
Materials and Methods
Patients and diagnostics
A total of 59 subjects were examined. Twenty-eight of them were admitted to the Heart 
Center of Semmelweis University (Table I). In 17 cases, acute coronary syndrome was the 
cause of admission, in which cases admission was immediately followed by taking the patient 
history and completing a thorough physical examination. Electrocardiography was made to 
determine if there was an ST elevation (> 1 mm). We used a troponin-T quick test as a 
specifi c marker of myocardial necrosis. Blood samples were collected for usual laboratory 
measurements and enzyme diagnostics (Table II). Laboratory results showed enzyme 
positivity in 10 cases (study group No. 1: enzyme positive acute coronary syndrome [EPACS], 
n = 10), the other patients were grouped as having enzyme negative acute coronary syndrome 
(study group No. 2: ENACS, n = 7). Urgent coronarography was completed in each of the 17 
cases by an experienced interventional cardiologist of our institute, who did not participate in 
this study. Coronarography showed signifi cant stenosis in 15 patients, in which cases 
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percutaneous coronary intervention (PCI) was performed immediately. Post-interventional 
coronarography showed good hemodynamic results. The other 11 patients enrolled in this 
study were admitted to the Heart Center with a known ischemic heart disease (angina pectoris 
or myocardial infarction in patient history) in a quiescent phase for a control examination. 
None of these patients suffered any pain related to their cardiac disease during the previous 
week of admission. Seven of them underwent elective coronarography, intervention was 
Table I. Patient characteristics
Enzyme positive 
ACS 
(n = 10)
Enzyme negative ACS 
(n = 7)
Ischemic heart 
disease 
(n = 11)
Sex (male/female) 4/6 4/3 6/5
Age (years) 71 (62–79) 57 (52–65)* 75 (62–76)
BMI (kg/m2) 23.8 (23.5–31.2) 25.3 (23.2–34.9) 25.3 (23.8–28)
Systolic pressure (mmHg) 128 (100–140) 132 (114–143) 120 (112–140)
Diastolic pressure (mmHg) 70 (50–72) 75 (65–79) 70 (70–77)
Heart rate (beats/min) 80 (73–85) 72 (65–75) 72 (67–81)
Ejection fraction (%) 50 (42.5–52.5) 56 (55–57.75)* 45 (32–55)
Risk factors
 Previous myocardial infarction 3 (30%) 1 (14%) 5 (45%)
 Previous PCI 3 (30%) 2 (29%) 7 (64%)
 Previous stroke 1 (10%) 0 (0%) 2 (18%)
 Current smoking 3 (30%) 2 (29%) 2 (18%)
 Diabetes mellitus 6 (60%) 1 (14%) 2 (18%)
 Hypertension 9 (90%) 7 (100%) 11 (100%)
 Hyperlipidaemia 7 (70%) 4 (57%) 9 (82%)
Drug therapy
 Aspirin 4 (40%) 4 (57%) 6 (55%)
 Ticlopidine 1 (10%) 0 (0%) 1 (9%)
 Clopidogrel 2 (20%) 3 (43%) 2 (18%)
 Oral anticoagulants 0 (0%) 2 (29%) 3 (27%)
 Beta-blockers 5 (50%) 5 (71%) 6 (55%)
 Calcium antagonists 3 (30%) 2 (29%) 3 (27%)
 ACE-inhibitors 7 (70%) 5 (71%) 7 (64%)
 Angiotensin-II antagonists 2 (20%) 3 (43%) 5 (45%)
 Nitrates 2 (20%) 2 (29%) 4 (36%)
 Statins 5 (50%) 4 (57%) 8 (73%)
 Oral antidiabetics 4 (40%) 1 (14%) 2 (18%)
 Insulin 1 (10%) 0 (0%) 0 (0%)
 Diuretics 4 (40%) 4 (57%) 7 (64%)
 Antiarrhythmics 3 (30%) 3 (43%) 6 (55%)
Values are expressed as median (interquartile ranges) or as the number of patients (percentages).
P values show differences compared to the enzyme positive ACS group (p < 0.05*)
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indicated and performed in four cases. All cardiologic patients underwent ultrasonography 
before being released from the hospital, all completed by the same cardiologist experienced 
in echocardiography. 
Exclusion criteria concluded liver or kidney failure, severe infl ammation or malignant 
disease in patient history, thrombolytic or immunosuppressive therapy and admission after 
more than 6 hours after the onset of chest pains. A group of 31 healthy people served as the 
control group, who were not aware of any disease and did not take any medication [15 males, 
16 females, age 36.2 (13.8), BMI 24.4 (4.0)]. We obtained a written informed consent from 
all participants. All patients were managed in accordance with the guidelines of the American 
College of Cardiology and the American Heart Association (3). The study was conducted in 
compliance with the ethical standards formulated at the 1983 revision of the Helsinki 
Declaration of 1975 and its protocol was approved by the Regional and Institutional 
Committee of Science and Research Ethics of Semmelweis University (205-1/2007). 
Blood samples
For N/OFQ measurements, we collected blood samples two days after coronarography. 
Samples were collected into vacutainer tubes with K-EDTA as an anticoagulant. Immediately 
after collection we added 100 μl aprotinin (0.6 TIU/ml) per tube as a protease inhibitor 
(Calbiochem). Samples were centrifuged at 1600 g for 15 minutes at 4 °C using a Janetzky 
K70 centrifuge. Plasma was transferred into Eppendorf tubes and was stored at –80 °C 
degrees until the measurements were conducted. Sample plasmas were then melted and 
loaded onto C-18 Sep-Pak cartridges and washed with 0.1% trifl uoroacetic acid (TFA). 
N/OFQ was eluted with 3 ml of 60% acetonitrile in 0.1% TFA, followed by freeze-drying. 
Validated N/OFQ radioimmunoassay (RIA) was performed at the Department of 
Pharmacodynamics using a commercially available kit (I125-NC-RIA, Phoenix Pharma-
ceuticals, CA, USA) with minimum sensitivity of 1 pg/ml. RIA was conducted in compliance 
with the protocol attached to the kit and as described before by Ko et al. (17). The assay was 
performed blind to the subject groups.
Statistical analysis
Plasma N/OFQ level means were compared between patient groups by Brown–Forsythe 
ANOVA accompanied by Games–Howell post hoc tests. The relationships of binary patient 
characteristic variables (coded by 0 and 1) with Plasma N/OFQ were studied by logit model. 
Factor analysis was used to classify patient characteristic variables together with plasma N/
OFQ and in order to reveal underlying hidden factors. Relationships between continuous 
patient characteristic variables and N/OFQ were explored by linear and nonlinear regression 
technique. Data are presented as median and interquartile range (IRQ). Statistical analyses 
were carried out by Statistica 8.0 (StatSoft Inc. Tulsa, OK, USA) and SPSS 15.0 (SPSS Inc. 
Chicago, IL, USA). The level of statistical signifi cance was established at α = 0.05.
Results
Median (IQR) plasma N/OFQ levels were found as follows: 6.86 (6.24–7.32) pg/ml for the 
group of enzyme positive acute coronary syndrome, 6.97 (6.87–7.01) pg/ml for enzyme 
negative acute coronary syndrome and 7.58 (7.23–8.20) pg/ml for ischemic heart diseases. 
We measured a level of 8.86 (7.27–9.83) pg/ml in the control group. We did not detect any 
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signifi cant difference between N/OFQ levels measured in male and female subjects. Analysis 
of plasma N/OFQ levels in the control group showed a much wider interquartile range 
compared to the other three groups. Further investigations are needed to clarify whether or 
not healthy people can be divided into subgroups regarding the plasma N/OFQ levels.
Owing to the apparent heteroscedasticity (Fig. 1 showing the interquartile ranges) 
analysis of variances were performed by Brown–Forsythe ANOVA. The main effect for 
N/OFQ was signifi cant, F(3, 50.8) = 21.6, p < 0.000. Post hoc tests revealed that N/OFQ was 
signifi cantly lower in all cardiovascular patients compared to the control group (EPACS 
p < 0.000, ENACS p < 0.000, IHD p = 0.05). Plasma N/OFQ levels in ischemic heart diseases 
at the same time were signifi cantly higher than what we measured in enzyme positive acute 
coronary syndrome (p = 0.009) and in enzyme negative acute coronary syndrome (p = 0.012). 
Fig. 1. Box and whisker plot of plasma N/OFQ levels show the median, minimum and maximum values 
and the interquartile ranges in the groups of enzyme positive ACS (n = 10), enzyme negative ACS (n = 7), 
ischemic heart diseases (n = 11) and in healthy control subjects (n = 31)
Statistical analyses of patient characteristics found the following variables also showing 
difference between the three patient groups (Table I). Age was signifi cantly higher in the 
enzyme positive ACS group compared to enzyme negative ACS (p = 0.02). In spite of this 
age difference together with the fact that all of the patient group’s ages were higher than that 
of the healthy control group’s age is not a covariate, thus, there was no need to control for this 
variable in N/OFQ ANOVA. Laboratory results showed (Table II) that CK was signifi cantly 
higher in the enzyme positive ACS group compared to enzyme negative ACS and to the 
ischemic heart disease group (both with p = 0.04). Admission glucose level was signifi cantly 
higher in the enzyme positive acute coronary syndrome compared to the other two groups 
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(p = 0.03 for ENACS and p = 0.04 for OHD). LDH difference between EPACS and ENACS 
groups were also signifi cant (p = 0.05). Echocardiography completed two days after admission 
showed that ejection fraction was signifi cantly lower in the EPACS group compared to the 
ENACS (p = 0.016). Other patient characteristic variables did not show signifi cant differences 
(Table II).
Table II. Clinical chemistry
Enzyme positive ACS 
(n = 10)
Enzyme negative ACS 
(n = 7)
Ischemic heart disease 
(n = 11)
Creatinine kinase (U/l) 818.50 (211.25–2861.50) 132.00 (81.50–148.00)* 95.00 (89.50–110.25)*
LDH (U/l) 802.50 (488.50–2475.00) 399.00 (333.00–483.50)* 552.00 (319.25–673.75)
CRP (mg/l) 26.630 (2.63–101.73) 2.50 (2.40–67.40) 2.70 (0.40–5.00)
HBDH (U/ml) 347.50 (230.25–1071.25) 167.50 (151.00–206.50) 191.50 (131.50–268.75)
INR 1.18 (1.03–1.20) 1.50 (1.10–1.89) 1.53 (1.05–2.00)
White blood cell count (G/l) 10.50 (6.23–19.08) 9.60 (7.40–13.20) 6.80 (5.30–10.00)
Platelet count (G/l) 214.50 (160.00–254.25) 223.00 (165.50–290.00) 214.00 (201.00–230.00)
Hb (g/l) 12.15 (10.33–13.00) 14.50 (11.80–15.55) 13.20 (12.50–13.90)
Serum sodium (mmol/l) 141.00 (137.75–142.75) 143.00 (140.50–146.50) 138.00 (137.00–141.00)
Serum potassium (mmol/l) 4.35 (3.93–4.53) 4.30 (3.95–4.40) 4.30 (4.10–4.90)
Cholesterol (mmol/l) 5.00 (2.50–5.55) 4.45 (4.40–5.25) 3.90 (3.35–4.55)
Trygliceride (mmol/l) 0.60 (0.50–1.05) 1.45 (0.80–2.48) 1.27 (0.90–1.50)
LDL (mmol/l) 4.10 (1.40–4.90) 3.30 (3.30–4.00) 2.80 (2.80–3.20)
HDL (mmol/l) 1.20 (0.90–1.70) 1.30 (0.83–1.48) 1.10 (0.93–1.58)
Admission glucose (mmol/l) 11.45 (6.25–17.45) 5.20 (5.03–6.43)* 5.70 (4.78–7.50)*
Fasting glucose (mmol/l) 6.40 (4.85–9.25) 6.25 (4.80–7.70) 5.70 (5.70–5.70)
ALP (U/l) 177.50 (92.25–193.00) 254.50 (171.50–302.25) 187.00 (134.50–253.00)
GOT (U/l) 35.00 (24.75–208.50) 20.00 (17.50–23.50) 23.00 (18.75–27.25)
GPT (U/l) 24.00 (17.50–44.50) 18.00 (14.50–33.00) 19.50 (13.50–33.00)
Serum creatinine (μmol/l) 95.50 (79.50–244.25) 90.00 (65.50–118.50) 109.00 (81.00–178.00)
Serum carbamide (mmol/l) 9.00 (5.38–19.13) 6.30 (4.90–10.35) 6.60 (5.25–10.33)
Nociceptin/orphanin FQ 
(pg/ml)
6.86 (6.24–7.32) 6.97 (6.87–7.01) 7.58 (7.23–8.20)**
Values are expressed as median (interquartile ranges) or as the number of patients (percentages).
LDH = lactate dehydrogenase; CRP = C-reactive protein; HBDH = hydroxybutyrate dehydrogenase; INR = In-
ternational Normalized Ratio; Hb = hemoglobin; LDL = low-density lipoprotein cholesterol; HDL = high-density 
lipoprotein-cholesterol; ALP = alkaline phosphatase; GOT = glutamate oxaloacetate transaminase; GPT = glutamic 
pyruvic transaminase.
P values show differences compared to the enzyme positive ACS group (* p < 0.05, ** p < 0.01)
Strong linear association was detected in the enzyme positive group between plasma 
N/OFQ levels and white blood cell (WBC) and platelet (PLT) count (Fig. 2, r = 0.93, p = 
0.0001 for WBC, and 0.69 with p = 0.03 for PLT) (Fig. 1). We noticed further signifi cant 
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correlations between N/OFQ levels of the subjects in the same group of enzyme positive ACS 
and creatine-kinase (CK), and plasma cholesterol level (correlation coeffi cients and p values 
were 0.73 with p = 0.02 for CK, and –0.66 with p = 0.05 for cholesterol) (Fig. 3). Signifi cant 
nonlinear (power) regression was found between N/OFQ and glutamate oxaloacetate 
transaminase (GOT) in EPACS group (R2 = 0.49, p = 0.03). N/OFQ has a nearly signifi cant 
nonlinear (quadratic) association with C-reactive protein (CRP) (R2 = 0.629, p = 0.07).
Fig. 2. Scatterplots showing the linear regression 
between the N/OFQ level and other laboratory 
parameters in the group of enzyme positive acute 
coronary syndrome (EPACS). 
A: N/OFQ and WBC count (r = 0.93, p = 0.0001). 
B: N/OFQ and platelet count (r = 0.69, p = 0.03).
C: N/OFQ and serum CK (r = 0.73, p = 0.02)
A
B
C
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Fig. 3. Scatterplots showing the 
linear regression between 
A: N/OFQ and cholesterol 
(r = –0.66, p = 0.05) and 
nonlinear regression between 
B: N/OFQ and C-reactive 
protein (R2 = 0.629, p = 0.07). 
C: N/OFQ and serum GOT 
(R2 = 0.49, p = 0.03). 
Outliers are not shown
A
B
C
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Based on the N/OFQ level measured in patient groups two binary variables could be 
predicted, pain and necroenzyme effl ux, using logistic regression. Low N/OFQ level predicted 
pain (Chi2 = 27.5, df = 1, p < 0.000) and necroenzyme effl ux (Chi2 = 7.8, df = 1, p = 0.005). 
Exploratory factor analysis classifi ed the 25-patient characteristic variable together with 
the plasma N/OFQ into three factors, which explain nearly equal proportions of the total 
variance. The factors represent common underlying hidden phenomena and are responsible 
for the covariation between the observed variables. The fi rst latent factor has an r = 0.92 
correlation with N/OFQ and the other variables in this factor are INR, platelet count, TG, 
SGOT and SGPT. The members of the second factor are age, heart rate, CRP, Hb, cholesterol, 
HDL, GGT, creatinine and urea. The third factor consists of the following patient characteristic 
variables: systolic blood pressure, serum CK, LDH, HBDH, EF, LDL, GLC admission and 
ALP. 
Discussion
We noticed signifi cantly lower plasma nociceptin/orphanin FQ levels in acute coronary 
syndrome patients after coronarography compared to healthy volunteers. Our results show 
that ACS is attached to the lowest levels of N/OFQ among the three disease groups examined. 
We found correlation between N/OFQ and GOT level in ACS as well. This fi nding suggests 
that N/OFQ levels of the plasma depends not only on the actual level of pain, but is very 
much dependent on whether there is an ischemic injury or not, followed by necrosis. 
In our previous studies, we have shown that chronic ischemic heart disease patients, 
suffering from chronic angina pectoris, have decreased nociceptin/orphanin FQ levels 
compared to healthy volunteers (18). We also have concluded that the severity of the 
atherosclerosis in the heart is in inverse relationship with circulating N/OFQ levels. In an 
elegant study, Fontana et al. (11) found that N/OFQ levels were elevated in patients with 
unstable angina. The authors implicated that higher nociceptin levels were due to repeated 
spontaneous episodes of angina. They also accomplished a plausible stress test with adenosine 
infusion, which showed that induced myocardial ischemia does not have any effect on the 
plasma N/OFQ levels. In our study, we noticed that enzyme positive acute coronary syndrome 
is attached to a lower level of N/OFQ compared to enzyme negative ACS, although the 
difference did not reach the level of signifi cance. We also have found that after ACS, 
nociceptin levels are signifi cantly correlated with higher GOT levels during the cardiac 
ischemia-necrosis. However, all these fi ndings are not in contradiction with the important 
study of Fontana et al. (11), since our patients were examined for nociceptin two days after 
the onset of acute coronary syndrome and their symptoms abolished after undergoing PCI. 
However, our results indicate that not only pain, but acute ischemic injury/necrosis also plays 
a role in the regulation of N/OFQ, as the only difference between enzyme positive ACS and 
the other disease groups was the presence of the acute ischemic injury in the heart.
We found a negative correlation between plasma nociceptin and cholesterol levels in 
the EPACS group. This result is in possible contradiction with recent studies, where 
intracerebroventricular nociceptin treatment was shown to increase cholesterol levels in mice 
(20). Stressful stimuli have also been shown to elevate total plasma cholesterol levels and 
activate endogenous opioid systems (4). Further studies are needed for explaining the 
relationship between plasma nociceptin and cholesterol levels during acute stress in humans. 
Guo et al. (13) noticed that myocardial ischemia up-regulated N/OFQ in dorsal root ganglia 
and spinal cord of rats. These interesting fi ndings are in line with our results, although the 
possible correlation of neural and blood plasma N/OFQ levels have not been examined yet.
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Stamer et al. (23) found lower pN/OFQ expression in the peripheral blood cells (PBC) 
of end-stage cancer patients and septic patients compared with healthy controls. They also 
showed that increased plasma procalcitonin, a marker of infl ammation, was associated with 
decreased pN/OFQ in all patient groups. However, NOP expression was upregulated in the 
same patient groups. The same study included postoperative patients with acute surgical 
stress. Interestingly, changes in postoperative patients were found to be minor compared to 
septic and cancer patients.
Plasma N/OFQ levels proved to be also elevated in ischemic stroke and transient 
ischemic attack patients (25). The conclusion of the study was that the increase in N/OFQ 
levels is the consequence of the neural ischemic injury. This fi nding also confi rmed that 
ischemic injury is in connection with the N/OFQ levels. 
Human studies carried out on females in the luteal phase suffering in fi bromyalgia 
syndrome have shown that N/OFQ level is linked to sex hormones (2). This is in agreement 
with the result of a previous in vitro study, which has shown that estrogen up-regulates the 
transcription of the N/OFQ precursor (29). Human studies having been made so far have not 
found any signifi cant difference between male and female patients suffering from cluster 
headache or from bipolar disorders (10, 26). We can affi rm this statement, as we did not fi nd 
any signifi cant difference between male and female subjects either in the patients’ groups or 
the controls. 
We found signifi cant correlations of N/OFQ and white blood cell counts, which provide 
further evidence of N/OFQ being regulated by immune cells beside the nervous system. The 
strong correlation between WBC and platelet counts and nociceptin levels suggest that 
plasma nociceptin levels might be WBC and platelet derived in ACS. Previous fi ndings of 
studies made on rodents have shown both in vivo and in vitro that the NOP receptor and N/
OFQ are expressed on peripheral mononuclear cells and neutrophils (1, 27). The connection 
between N/OFQ and infl ammation has been also confi rmed in a human study conducted on 
critically ill patients with sepsis (28). Plasma N/OFQ concentrations were found higher in 
patients who died within 30 days compared to survivors, however no correlation was detected 
between plasma N/OFQ concentrations and markers of illness severity and organ dysfunction. 
How decreased plasma nociceptin/orphanin FQ levels after acute coronary syndromes affect 
immune/ infl ammatory functions remains to be further elucidated. It is not obvious whether 
lower N/OFQ levels would mean impaired immune functions after ACS, since WBC 
nociceptin receptor expression levels have not yet been investigated during acute cardiac 
ischemia/reperfusion. However, temporary impairment of immune functions could be 
benefi cial by modulating the healing process of the myocardium after an acute ischemic 
event.
Study limitations: The major limitation of our study is the relatively small number of the 
whole patient cohort. However, this is the fi rst, small number investigation related to 
ischemia/necrosis and plasma nociceptin/orphanin FQ levels after acute myocardial 
infarction. Further investigations are needed and a larger number of acute coronary syndrome 
cohorts with differing extents of the disease should be investigated in the future to confi rm 
the novel fi ndings of our study.
Our fi ndings indicate that the presence of acute coronary syndromes is closely associated 
with lower plasma N/OFQ levels after coronarography. Both enzyme positive and negative 
ACS are attached to a very low level of plasma N/OFQ, even compared to quiescent ischemic 
heart diseases. As we found correlation between N/OFQ and CK and WBC count in the 
enzyme positive ACS group, it seems that not only pain sensation, but also ischemic injury 
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and the concomitant infl ammatory response may have a role in regulating the plasma level of 
N/OFQ. Further studies are needed to examine the relevance and effects of acute ischemic 
stress on the N/OFQ system and to decide whether the lower N/OFQ level is a cause or a 
consequence of the acute ischemic heart disease.
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